期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 18, 期 11, 页码 1581-1594出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543780903151806
关键词
1D09C3; 4-demethylpenclomedine; ARQ-171; AZD-4992; CNF-1010; DN-101; FCE-28068; FCE-28069; folitixorin calcium; huMy9-6-DM4; INNO-305; mitumprotimut-T; MLN-8054; N-acetylcysteine; PD-0325901; phosphomannopentaose sulfate; PI-166; SGX-523; spisulosine; Symadex; tozasertib lactate; varalanib; zanolimumab
The failure of drug candidates in clinical development remains a critical issue for the pharmaceutical and biotechnology industries. This article documents those oncology drugs discontinued in 2008 and briefly reviews reasons for termination of development. Source information was derived from a search of the Pharmaprojects database for drugs reaching phase I - III clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
